creat next frontier surgeri
deal make heat medical-technolog industri devic
maker hunt innov product boost growth surgic instrument
busi expect reach biggest
player space includ
decemb medtron plc complet deal acquir mazor robot
ltd isra compani whose robotics-assist product aid spine brain
johnson johnson work disrupt medic innov
announc februari subsidiari ethicon inc enter
definit agreement acquir auri health inc cash
addit conting payment aggreg may
acquisit help develop digit tool diagnosi early-stag
intervent lung cancer area compani increasingli
focus auriss tool could allow lung cancer caught earlier
abl reach lung conduct minim invas biopsi
health-car giant explor option treat earlier-stag lung cancer
tool
addit advanc compani focus initi combat lung
cancer auri health technolog support johnson johnson vision
world leader across continuum surgic approach includ
open laparoscop robot endolumin
sale js medic devic unit recov sinc turnaround
effort began compani expect unit achiev
above-market growth would expect move aggress
robot field gap medic devic busi
johnson johnson announc ethicon inc enter definit
agreement acquir auri health inc cash addit
conting payment aggreg may payabl upon
auri health privat held develop robot technolog initi
focus lung cancer fda-clear platform current use
bronchoscop diagnost therapeut procedur
auri part js medical-devic divis world largest maker
health-car product also robotic-surgeri compani call verb
surgic inc form verili life scienc part googl parent
alphabet inc late
auri found surgic robot pioneer freder moll join
johnson johnson upon complet transact close subject
anti-trust clearanc customari close condit transact
expect close end compani discuss
transact next quarterli earn call april
auriss flagship product robot use surgeon via control direct
scope patient bodi camera devic call monarch
approv regul last year diagnost therapeut
bronchoscop procedur instrument insert nose
auri health current focu lung cancer monarch platform robot
technolog play import role within lung cancer initi
johnson johnson enabl develop differenti digit
solut address key step lung cancer care journey
diagnosi earli stage intervent central jnj commit
develop solut prevent intercept cure deadli diseas
transact also complementari acquisit orthotaxi
robot technolog orthoped continu develop verb
surgic platform strateg partnership verili acquisit
acceler johnson johnson entri robot potenti
growth expans intervent applic
 js share margin midday trade intuit
surgic fell much analyst said auri could becom
formid competitor given js commerci scale js stock gain
past year compar growth record industri
new era health care aim simplifi surgeri drive effici
reduc complic improv outcom patient ultim make
surgeri safer collect technolog togeth market-lead
medic implant solut creat foundat comprehens
digit ecosystem help support surgeon patient
surgeri
auri health inc incorpor base redwood citi
california auri transform medic intervent introduct
monarch platform monarch platform auri seek leverag
power flexibl robot enabl new possibl endoscopi use
small camera tool enter bodi natur open
monarch platform integr latest advanc robot micro-
instrument endoscop design sens data scienc one platform
improv outcom reduc cost monarch platform intend
diagnost therapeut bronchoscop procedur
dr moll said thrill join johnson johnson help push
boundari possibl medic robot improv live
patient across globe togeth abl dramat
acceler collect product innov develop new intervent
solut redefin optim patient outcom
combin testament incred work auri health team
innov engin behind monarch platform repres
huge step forward endolumin technolog dr moll look forward
continu shape futur intervent ad expertis
resourc world largest healthcar organ
relaunch johnson babi product strengthen busi
maintain hold rate upgrad
tp previous deriv
estim base forward price-to-earnings multipl
adjust ep give upsid
potenti expect top-
line growth
estim base follow factor
market perform segment strong
sale momentum consum segment continu
growth medic devic segment new product
launch quarter acquisit made
strengthen busi relaunch johnson babi
deliv strong perform quarter
increas revenu growth
ep strong perform due
market growth pharmaceut segment strong sale
momentum consum segment continu growth
busi deliv market growth
due growth oncolog product total revenu
increas key product
led growth zytiga imbruvica
stelara darzalex tremfya
world-wide consum sale increas
perform posit impact
restock retail inventori support relaunch
johnson babi product result outsid
 led asia pacif region dr ci labo
neutrogena brand strong uptak
compani namejohnson johnsontickerjnjstock ratingholdunchangedindustri viewoverweightpositivepric week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth johnson johnson| februari
world-wide medic devic sale grew
continu strengthen market lead
posit electrophysiolog vision busi
also improv perform spine keen
recommend hold rate stock price
increas quarter estim base
jnj perform strong growth pharma
announc agre ci hold
co ltd launch all-cash offer acquir
outstand share compani alreadi held
affili per share equat
acquisit includ compani rang
brand compris dr ci labo labo labo genom
line skincar product
expect revenu rang
adjust ep expect rang
current price-to-earnings averag price-to-earnings
due increas stock price price-to-earnings
volatil past due volatil stock price
movement trend ep price-to-earnings trail
expect forward price-to-earnings multipl
recommend hold rate expect
revenu grow
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date dec ex-dividend date last split factor new per last split date jun inform johnson johnson| februari
incom statement item total gross research sale gener restructur merger oper total oper oper interest incom incom provis incom net incom avail common ep ep weight averag share estim annual actual annual actual quarterli johnson johnson| februari
cash short-term total defer incom prepaid current total current net properti plant intang defer incom long-term total non-curr total short-term account tax accru current total current long-term defer tax long-term total non-curr total common retain treasuri accumul comprehens total stockhold total liabil stockhold balanc sheet itemsactu annual actual quarterli johnson johnson| februari
period cash flow oper due net earn
non-cash expens adjust depreci amort stock-bas
compens asset write-down relat alio asset defer tax provis
period cash use invest activ use addit
properti plant equip net purchas invest market
secur acquisit
period cash use financ activ use dividend
sharehold net retir short long term debt repurchas
common stock
depreci investment/asset impair defer incom stock base chang work account work non-cash net cash provid oper invest properti plant acquisit purchas sales/matur invest net cash use invest debt debt common stock dividend financ net cash provid use financ effect exchang rate net chang begin end johnson johnson| februari
deliv strong third-quart perform reflect continu
above-market growth busi acceler sale
momentum consum busi consist progress medic
compar
jnj revenu increas compar
oper sale increas neg
impact currenc net impact acquisit
divestitur world-wide oper sale growth neg
total revenu increas
compar total intern revenu increas
compar
cog revenu
decreas
compar
sale compani europ grew includ
oper growth neg currenc impact
sale compani western hemispher exclud declin
includ oper growth off-set
neg currenc impact
sale compani asia-pacif africa region grew
includ oper growth neg
currenc impact
cog decreas compar
cog revenu decreas compar
declin due lower acquisition-rel cost
favor product segment mix
johnson johnson| februari
sg expens increas compar
sg expens revenu declin
compar declin due lower
cost rel sale growth pharmaceut busi
 expens decreas compar
 sale decreas
compar decreas due time specif
lower mileston payment pharmaceut busi
record ipr charg partial
impair charg relat develop program
investig drug treatment respiratori syncyti viru rsv
human metapneumoviru hmpv acquir acquisit
late inform becam avail led suspend on-
go phase trial analysi inform
sg expens
revenu declin
compar
compar
inform becam avail enabl reassess
carri valu ipr asset impair charg
calcul base updat cash flow project discount inher
risk asset develop reflect impact recent phase clinic
trial suspens decreas probabl success factor
on-going analysi asset develop activ
continu evalu inform respect develop program
monitor remain intang asset impair
addit impair charg record
discontinu develop project anti-thrombin antibodi
associ acquisit limit
interest expens net compar
interest expens slightli higher due higher averag interest
rate partial off-set lower averag debt balanc
increas
compar
period
increas
oper growth
compar
sale
expens declin compar incom
declin attribut revers conting
liabil lower litig expens off-set
higher gain divestitur primarili compe
effect tax rate declin compar
adjust tax rate compar
net earn increas compar
net earn includ after-tax intang
amort expens net charg after-tax special item
primarili consist non-cash charg attribut partial write-
in-process research develop asset associ
acquisit alio biopharma inc
net margin compar
adjust net earn increas compar
gaap ep increas compar
adjust ep increas compar
period world-wide sale increas
includ oper growth compar sale
currenc fluctuat posit impact
month period period net impact
acquisit divestitur world-wide oper sale growth
sale compani increas period
compar prior year period
net impact acquisit divestitur oper sale
growth posit
period sale intern compani increas
includ oper growth posit
currenc impact compar period
period net impact acquisit divestitur
intern oper sale growth posit
period sale compani europ achiev
growth includ oper growth posit
currenc impact
period sale compani
hemispher exclud achiev growth includ
oper growth partial off-set neg currenc impact
period sale compani asia-pacif
africa region achiev growth includ oper growth
posit currenc impact
geograph sale distribut period bn
sale intern
compani increas
growth
compar
period
period sale
compani asia-
achiev growth
oper growth
posit
currenc impact
net
compar
increas
compar
period cog increas
compar period cog
sale increas compar
unfavor increas due higher amort expens primarili relat
actelion acquisit partial off-set lower acquisit relat
cost favor product segment mix
period sg expens increas
compar period sg
expens sale declin compar
decreas due lower cost rel sale growth
busi decreas partial off-set invest
spend support new product launch medic devic consum
period expens increas
compar expens sale decreas
compar
period interest expens net
compar period expens
net compar
period effect tax rate
compar adjust tax rate
compar
period net earn increas
compar period
adjust net earn increas compar
period net margin
compar
period ep increas
compar adjust ep increas
compar
divid major segment consum segment
medic devic segment contribut sale
consum segment contribut sale medic devic
segment contribut
total revenu consum segment increas
compar consist oper
increas neg currenc impact
month period total revenu increas
compar
total revenu increas
compar total intern revenu decreas
compar
world-wide oper result exclud net impact acquisit
divestitur due over-the-count product includ motrin
tylenol analges zyrtec upper respiratori imodium digest
health product beauti product includ neutrogena ogx dr ci
labo well domest sale johnson babi care product
sale consum
sale
contribut
total revenu
increas
compar
world-wide revenu
increas
compar
world-wide revenu
increas
compar
due new
world-wide revenu beauti product increas
compar
period total revenu increas compar
total revenu declin
compar total intern revenu increas
compar
beauti growth due neutrogena vogu neostrata
product well strength dr ci labo dabao product outsid
world-wide revenu oral product increas
compar due new product launch
period total revenu increas
compar
total revenu increas
compar total intern revenu declin
compar
world-wide revenu over-the-counter product increas
compar period
total revenu increas compar
total revenu increas
compar total intern revenu increas
compar
growth due increas consumpt growth across multipl
brand includ zyrtec tylenol children motrin well
digest health product anti-smok aid sale recent
acquisit zarbe also contribut growth
world-wide revenu
compar
world-wide revenu
product decreas
compar
world-wide revenu women health product decreas
compar due increas
sale latin america period total revenu increas
compar
total revenu flat total
intern revenu declin compar
world-wide revenu babi product declin
compar period
total revenu declin compar
world-wide revenu
decreas
compar
total revenu increas
compar total intern revenu decreas
compar
babi franchis achiev oper growth compar
previou year quarter due relaunch pipelin
pharmaceut
segment increas
compar
world-wide revenu wound product decreas
compar
month period total revenu decreas
compar
total revenu increas
compar total intern revenu declin
compar
wound care/oth franchis revenu declin due divestitur
compe
world-wide revenu pharmaceut segment increas
compar
month period total revenu increas
compar segment deliv strong
market growth due double-digit growth nine key product
total revenu increas
compar total intern revenu increas
compar
growth
due strong
uptak strong uptak
stelara crohn
indic
aria launch
tremfya
neg impact
lower sale
due increas
discounts/reb
world-wide immunolog revenu increas
compar period total
revenu increas compar
total immunolog revenu decreas
compar total intern revenu
increas compar
growth immunolog product due strong uptak strong
uptak stelara crohn diseas expand indic
simponi/simponi aria launch tremfya immunolog
market growth immunolog neg impact lower sale
remicad infliximab due increas discounts/reb biosimilar
simponi/simponi aria revenu increas
compar period
total revenu increas compar
total revenu increas
total intern revenu increas
stelara revenu increas compar
period total revenu
increas compar
total revenu increas
total intern revenu increas
remicad revenu declin compar
period total revenu
decreas compar
total revenu declin
revenu export declin total
intern revenu increas
world-wide revenu cardiovascular decreas
compar period
total revenu declin compar
total cardiovascular revenu declin
compar total intern revenu
decreas compar
revenu increas
compar
cardiovascular
decreas
compar
xarelto revenu increas compar
period total revenu
increas compar
invokana invokamet revenu decreas
compar period
total revenu declin compar
total revenu declin
total intern revenu increas
world-wide revenu oncolog increas
compar period
total revenu increas compar
total oncolog revenu increas
compar total intern revenu
increas compar
growth due strong sale darzalex imbruvica due
increas patient uptak global sale zytiga due latitud
data market growth sale launch erleada
contribut growth
darzalex revenu increas
compar period total
revenu increas compar
total revenu increas
total intern revenu
increas
compar
oncolog increas
compar
imbruvica revenu increas
compar period total
revenu increas compar
total revenu increas
total intern revenu increas
zytiga revenu increas compar
period total revenu
increas compar
world-wide revenu pulmonari hypertens increas
compar
month period total revenu increas compar
total revenu increas
compar total intern revenu declin
compar
growth due strong sale opsumit uptravi due
continu market growth share gain partial off-set lower sale
tracleer due gener market share loss opsumit
opsumit revenu increas compar
period total revenu
increas total revenu increas
total intern revenu increas
increas
compar
world-wide revenu
increas
compar
tracleer revenu decreas
compar period total
revenu increas total revenu
 declin total intern
revenu declin
uptravi revenu increas compar
period total revenu
increas compar total
revenu increas total
intern revenu increas
world-wide revenu infecti diseas product increas
compar
month period total revenu increas
compar
total revenu declin
compar total intern revenu increas
compar
growth infecti diseas product due strong sale
prezcobix/rezolsta continu success odefsey launch
symtuza juluca off-set lower sale prezista
edur revenu increas compar
period total revenu
increas compar
total revenu declin total
intern revenu increas
world-wide revenu
product increas
compar
growth infecti
diseas product
due strong sale
continu success
odefsey launch
symtuza juluca
off-set lower sale
prezista prezcobix rezolsta symtuza revenu increas
compar
month period total revenu increas
compar total revenu declin
total intern revenu increas
world-wide revenu neurosci product decreas
compar
month period total revenu increas
compar
total revenu increas
compar total intern revenu decreas
compar
growth due strong sale invega sustenna/xeplion
/trinza /trevicta off-set cannib risperd
consta gener competit concerta /methylphenid
invega sustenna xeplion trinza trevicta revenu increas
compar
period total revenu increas
compar total revenu increas
total intern revenu increas
concerta methylphenid revenu decreas
compar period
total revenu increas compar
total revenu decreas
total intern revenu increas
neurosci
product decreas
compar
increas
compar
medic devic
segment decreas
compar
diabet
product decreas
compar
world-wide revenu medic devic segment decreas
compar
period total revenu increas
compar
total revenu increas
compar total intern revenu increas
compar
growth due consist sale momentum due intervent
solut advanc surgeri vision
world-wide revenu diabet product decreas
compar
month period total revenu decreas
compar
lower sale due jnj decis exit anima insulin pump
busi price declin competit pressur subsequ
quarter complet divestitur lifescan busi
total revenu decreas
compar total intern revenu decreas
compar
intervent
solut increas
compar
orthoped
decreas
compar
world-wide revenu intervent solut increas
compar
month period total revenu increas
compar
total revenu increas
compar total intern revenu increas
compar
intervent solut franchis includ cerenovu busi
previous includ spine orthopaed achiev strong
oper sale growth strong oper
growth electrophysiolog busi due atrial fibril
procedur growth continu uptak thermocool
world-wide revenu orthoped decreas
compar period
total revenu decreas compar
total revenu decreas
compar total intern revenu decreas
compar
orthopaed franchis experienc oper sale declin
declin spine sale due codman
neurosurgeri divestitur share loss spine partial off-set new
trauma flat compar prior year due lower market growth
continu price pressur oper growth hip
knee due continu uptak new product
total revenu hip product increas
compar period total
revenu increas compar
total revenu increas
total intern revenu decreas
total revenu trauma product decreas
compar period
total revenu declin total
intern revenu decreas
total revenu spine product declin
compar period total
revenu declin
total revenu knee product declin
compar period total
revenu declin
world-wide revenu surgic product increas
compar
period total revenu increas compar
total revenu increas
compar total intern revenu increas
compar
advanc surgeri revenu increas
compar total revenu increas
total intern revenu increas
total revenu
decreas
compar
surgic product
increas
compar
revenu increas
compar
total revenu
increas
compar
gener surgeri revenu decreas
compar period total
revenu increas compar
total revenu decreas
total intern revenu increas
specialti surgeri revenu increas
compar period total
revenu increas compar
total revenu declin
total intern revenu increas
oper growth advanc surgeri led endocutt biosurgeri
product growth outsid energi product oper
growth gener surgeri led wound closur product oper
growth specialti surgeri led advanc steril product
total revenu vision care product increas
compar period
total revenu increas total revenu
 increas total intern
revenu increas
contact lens revenu increas
compar total revenu increas
total intern revenu increas
oper growth led strength
astigmat daili dispos lens oasi contact lens
surgic revenu increas compar
total revenu
total intern revenu surgic
growth led cataract perform outsid
quarter fda approv addit indic
imbruvica ibrutinib combin rituximab non-
chemotherapi combin regimen patient rare blood cancer
european commiss ec grant market author
darzalex daratumumab combin velcad bortezomib
proteasom inhibitor melphalan alkyl agent prednison
treatment newli diagnos multipl myeloma patient inelig
autolog stem cell transplant
fda approv ec grant market author symtuza
d/c/f/taf complet darunavir-bas single-tablet regimen
treatment infect
new drug applic submit fda esketamin nasal
spray rapidli act antidepress treatment-resist depress
adult erdafitinib once-daili oral pan-fibroblast growth factor
receptor fgfr inhibitor treatment local advanc metastat
supplement new drug applic submit fda seek
broaden use imbruvica ibrutinib chronic lymphocyt
leukemia small lymphocyt lymphoma includ combin use
non-chemotherapi agent obinutuzumab frontlin set
type ii variat submit european medicin agenc ema
seek expand indic opsumit macitentan includ
treatment adult inoper chronic thromboembol pulmonari
hypertens cteph group improv exercis capac
also submit supplement biolog licens applic fda
type ii variat ema seek approv split dose
regimen darzalex daratumumab
darzalex
daratumumab
combin
drug applic
submit fda
seek broaden
use imbruvica
ibrutinib chronic
lymphocyt leukemia
also enter
licens agreement
pharmaceut inc
develop
treatment chronic
fda approv addit indic xarelto rivaroxaban
reduc risk major cardiovascular cv event cv death
myocardi infarct stroke peopl chronic coronari
market author applic submit ema
esketamin nasal spray rapidli act antidepress treatment-
resist depress adult
also enter exclus world-wide licens agreement
arrowhead inc develop commerci new
treatment chronic hepat viral infect
quarter receiv european ce mark approv bravo
divert use treatment patient suffer intracrani
acquisit emerg implant technolog gmbh privat held
manufactur titanium interbodi implant spinal fusion
surgeri complet
accept bind
offer fortiv
corpor acquir
advanc steril
product busi
aggreg valu
billion subject
accept bind offer corpor acquir
advanc steril product busi aggreg valu
billion subject customari adjust
announc complet divestitur lifescan busi
platinum equiti subject customari adjust
revenu
expect
rang
improv bp
improv bp
revenu expect rang
effect tax rate expect rang
adjust ep expect rang
net interest expens expect rang
adjust ep expect
rang
deliv strong quarterli result due discuss market growth
segment continu sale momentum medic devic
segment acceler sale momentum consum segment total
revenu increas adjust ep growth
busi deliv market growth due growth
oncolog product total revenu increas
key product led growth zytiga imbruvica stelara
darzalex tremfya
world-wide consum sale increas
perform posit impact restock retail inventori
support relaunch johnson babi product result
outsid led asia pacif region dr ci labo
neutrogena brand strong uptak
complet acquisit zarbe inc leader naturally-bas
healthcar product complet acquisit emerg implant
technolog gmbh privat held manufactur titanium
interbodi implant spinal fusion surgeri
bind offer accept corpor acquir advanc
steril product busi aggreg valu subject
platform design assess nerv statu identifi avoid peripher
nerv spine surgeri
ytd stock perform compar
roa roi roe ttm basi respect
quarterli result due
market growth
pharmaceut
momentum medic
devic segment
momentum consum
non- reconcili
non- reconcili
non- reconcili
y/i revenu growth ttm compar
y/i ep growth ttm compar
gross margin declin ttm compar due increas cog
oper margin declin ttm compar due increas expens
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth johnson johnson| februari
mrqgross mrqcog mrqoper mrqnet mrqsg mrqr sale johnson johnson| februari
invest flow
mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqfinanci mrqreturn mrqreturn asset johnson johnson| februari
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item johnson johnson| februari
balanc sheet item
outstand equival market debt common prefer stock- purchas properti plant sale properti plant purchas sale business- purchas sale issuanc stock- repurchas net issuanc prefer stock- net issuanc net chang capit free johnson johnson| februari
current price-to-earnings averag price-to-earnings due increas stock price price-to-earnings
volatil past due volatil stock price movement trend ep
price-to-earnings trail expect forward price-to-earnings
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluevanguard group inc state mutual automobil insur northern trust geod capit manag massachusett servic america capit world top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard spdr etf vanguard institut fund-institut fidel ishar washington mutual investor vanguard -valu mf seri trust i-mf valu select sector spdr fund-health johnson johnson| februari
developmentsjanssen receiv posit chmp opinion erleada apalutamid patient non-metastat castration-resist prostat cancer high risk develop metastat diseasenovemb janssen compani johnson johnson announc committe medicin product human use chmp european medicin agenc ema issu posit opinion apalutamid next gener oral androgen receptor inhibitor treatment adult patient non-metastat castration-resist prostat cancer nmcrpc high risk develop metastat diseas chmp posit opinion review european commiss ec author grant approv use apalutamid fda approv invokana canagliflozin reduc risk heart attack stroke cardiovascular death adult type diabet establish cardiovascular diseaseoctob janssen compani johnson johnson announc food drug administr fda approv invokana canagliflozin reduc risk major advers cardiovascular cv event includ heart attack stroke death due cardiovascular caus adult type diabet establish cv diseas invokana first oral diabet treatment approv indic johnson johnson announc offer acquir ci hold co ltd octob johnson announc agre withci hold co ltd japanes compani focus market develop distribut broad rang dermocosmet cosmet skincar product launch all-cash offer tender offer acquir outstand share compani alreadi held byjohnson johnsonand affili per share equat acquisit includ compani rang brand comprisingdr ci labo labo laboand genom line skincar product janssen announc exclus world-wide licens agreement develop commerci new treatment chronic hepat viral infectionoctob janssen compani johnson johnson today announc janssen inc janssen enter agreement inc arrowhead exclus world-wide licens develop commerci aro-hbv phase subcutan ribonucl acid interfer rnai therapi candid investig treatment chronic hepat viral infect johnson johnson| februari
perform
compar
gross margin ttm
compar
industri
roa roi roe
ttm basi
respect
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit consensu view analyst trend stock
forecast expect
forward price-to-earnings
higher
jnj avgfive-year growth forecast usdgrowth high day day day estim comparisonjnjindustri avg avgprice/earn yield johnson johnson| februari
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr
next qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last last dayserrorerrorerrorerrordown last dayscurr surprisescurr growth rate johnson johnson| februari
stock price volatil quarter dip octob
averag volum share trade period total return given
period
stock price show dip later show upward trend surg
novemb
stock gave return past one year rang stock
stock price show upward trend past dip decemb may
stock given return past
recommend hold rate tp estim adjust ep
estim growth revenu deliv strong quarterli perform
due market growth pharmaceut busi acceler sale momentum consum busi
consist progress medic devic busi expect top-lin revenu grow
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host ofclient
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com orcontact
